Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AT-1401
- Development stage
- Preclinical
- Lead developer
- Wakamoto
- Modality
- Small Molecules
- Administration
- Ophthalmic
01
Overview
AT-1401 is a preclinical-stage small molecule therapeutic being developed by Wakamoto Pharmaceutical for the treatment of dry eye. The drug is characterized by a thermo-responsive formulation designed to function as an artificial tear. This technology allows the formulation to remain in a liquid state at room temperature for ease of administration, while transitioning to a gel-like state upon contact with the ocular surface temperature. This phase change is intended to enhance the residence time of the lubricant on the eye, thereby providing sustained relief from dry eye symptoms and improving the efficacy of the artificial tear compared to conventional formulations.
Beyond the preview
Go deeper on AT-1401.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AT-1401.